Status:
UNKNOWN
Exhaled Breath Particles in Lung Cancer
Lead Sponsor:
Lund University Hospital
Conditions:
Lung Cancer
Non-small Cell Lung Cancer
Eligibility:
All Genders
16-90 years
Brief Summary
Lung cancer (CaP) is the leading cause of cancer related deaths on a global level. Early diagnosis is vital for survival and life quality of the affected patients, yet lung cancer is often diagnosed a...
Detailed Description
EBP samples and measurements of PFR will be collected from patients with primary non-small cell lung cancer (NSCLC) at Skåne University Hospital (SUS) Lund. Measurements will be done at 2 time points,...
Eligibility Criteria
Inclusion
- Primary lung cancer with clinical Tumor, Node, Metastasis (TNM) up to cT3N1M0 according to TNM 7th edition
- Able to take instructions and perform the standardized breathing maneuver
Exclusion
- Dementia
- Severe neurological disease
- Drug abuse
- Heart failure New York Heart Association (NYHA) Classification, NYHA class III or IV
- Ejection fraction \< 50 %
- S-creatinine \> 140 µmol/L
- Poorly regulated diabetes mellitus
Key Trial Info
Start Date :
January 23 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05395611
Start Date
January 23 2018
End Date
January 1 2025
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skåne University Hospital
Lund, Skåne County, Sweden, 224 60